Compounds and methods for kinase modulation, and indications therefor

A compound of Formula (I′):

• or a pharmaceutically acceptable salt, a Solvate, a tautomer, an isomer, or a deuterated analog thereof,
• wherein:
• (i) R1 and R2 are taken together to form an optionally substituted 5- or 6-membered fused ring having from 0-3 heteroatoms as ring members selected from N, O or S, wherein one or two ring carbon atoms are optionally replaced by —C(═O)—;
• or
• (ii) R1 is H, halogen, C1-4alkyl C1-4haloalkyl, C1-4haloalkoxy, cyclopropyl or a lone pair of electrons and R2 is —NH-L2-R6 wherein R6 is B, optionally substituted aryl, optionally substituted arylC1-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl-C1-4alkyl, optionally substituted heterocycloalkyl, optionally substituted C1-4alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl-C1-4alkyl, optionally substituted heterocyclyl or optionally substituted heterocyclyl-C1-4alkyl;
• and wherein L2 is selected from a bond, —C(O)—, —C(O)N(Rf)—, —SO2N(Rf)—, —SO2—, —C(O)O—, —C(═NRf)N(Rf)—, wherein each Rf is independently H or C1-4alkyl;
• G is an optionally substituted C1-4alkyl, an optionally substituted aryl or an optionally substituted 5 or 6-membered heteroaryl having one or more nitrogen atoms as ring members, wherein the aryl or heteroaryl is optionally fused with an optionally substituted 5 to 8-membered ring having from 0-2 heteroatoms as ring members selected from O, N or S;
• L1 is selected from —CH(OH)—, —C(O)NR5—, —CH2N(R5)—, —SO2N(R5)—, —N(R5)C(O)N(R5)—, —N(R5)SO2—, —N(R5)CH2—, —OC1-4alkylene-, —C1-4alkylene-O—, —C(O)—, —NR2C(O)—, —SO2—, —N(R5)SO2N(R5)—, —SON(R5)— or —S(O)—, wherein each R5 is independently H or C1-4alkyl;
• Y1 is N or C;
• Y2 is N or optionally substituted ═C—;
• and
• Y3 is N or CH;
• with the proviso that Y1, Y2 and Y3 are not simultaneously N.